Cargando…

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

Detalles Bibliográficos
Autores principales:	Zolla-Pazner, S, Wrin, T, Seaman, MS, Yu, X, Wood, B, Self, S, Hioe, CE
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767909/ http://dx.doi.org/10.1186/1742-4690-6-S3-P395

Ejemplares similares

Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes
por: Hioe, Catarina E., et al.
Publicado: (2010)

P04-10. Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies
por: Gorny, MK, et al.
Publicado: (2009)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies
por: Shen, Guomiao, et al.
Publicado: (2015)

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations
por: Upadhyay, Chitra, et al.
Publicado: (2018)

Skin tattooing as an effective tool for delivering DNA and protein vaccine immunogens
por: Chiu, Y, et al.
Publicado: (2012)

P05-14 LB. Analysis of virus swarms to identify vaccine immunogens with improved exposure of epitopes recognized by broadly neutralizing antibodies
por: Berman, P, et al.
Publicado: (2009)

P04-51 LB. The epitopes of two newly identified broad and potent neutralizing antibodies, PG9 and PG16
por: Walker, L, et al.
Publicado: (2009)

P04-53 LB. Potent and broad HIV-specific neutralizing antibodies in infants are not associated with prevention of mother to infant HIV transmission
por: Lynch, J, et al.
Publicado: (2009)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

P04-47. High-titer autologous and heterologous neutralizing antibody activity in acute SIV-infection
por: Schweighardt, B, et al.
Publicado: (2009)

Broadly Neutralizing Antibodies for HIV-1 Prevention
por: Walsh, Stephen R., et al.
Publicado: (2021)

An in vitro methodology for discovering broadly-neutralizing monoclonal antibodies
por: Ahmadi, Shirin, et al.
Publicado: (2020)

Comparative Magnitude of Cross-Strain Conservation of HIV Variable Loop Neutralization Epitopes
por: Swetnam, James, et al.
Publicado: (2010)

P04-54 LB. Genetic signature analysis identifies the CD4i region of gp120 as a determinant of broadly NAb responses in HIV-1-infected individuals
por: Gnanakaran, G, et al.
Publicado: (2009)

Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1
por: Lim, Angeline PC, et al.
Publicado: (2008)

Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies
por: Frey, Gary, et al.
Publicado: (2010)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Broad neutralization of SARS-related viruses by human monoclonal antibodies
por: Wec, Anna Z., et al.
Publicado: (2020)

Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity
por: Zolla-Pazner, Susan, et al.
Publicado: (2015)

Residue 315 regulates V3 exposure and V3 antibody recognition on HIV subtype B and C viruses
por: Manhas, S, et al.
Publicado: (2012)

Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration
por: Sharma, Vaneet K., et al.
Publicado: (2020)

Broadly neutralizing monoclonal antibodies against human adenovirus types 55, 14p, 7, and 11 generated with recombinant type 11 fiber knob
por: Tian, Xingui, et al.
Publicado: (2018)

Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
por: Almond, David, et al.
Publicado: (2012)

A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch
por: Wang, Zijun, et al.
Publicado: (2020)

Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
por: Evans, MC, et al.
Publicado: (2012)

Human Monoclonal Antibodies Broadly Neutralizing against Influenza B Virus
por: Yasugi, Mayo, et al.
Publicado: (2013)

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
por: Tortorici, M. Alejandra, et al.
Publicado: (2021)

A humanized anti-human adenovirus 55 monoclonal antibody with good neutralization ability
por: Chen, Lei, et al.
Publicado: (2023)

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method
por: Evans, Mark C, et al.
Publicado: (2014)

A broadly neutralizing monoclonal antibody induces broad protection against heterogeneous PRRSV strains in piglets
por: Zhang, Zhigang, et al.
Publicado: (2021)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

Biophysical dissection of the antigen-antibody interaction of the broadly reactive anti-V3 human mAb 447-52D
por: Killikelly, A, et al.
Publicado: (2012)

Epitope Mapping of Conformational V2-specific Anti-HIV Human Monoclonal Antibodies Reveals an Immunodominant Site in V2
por: Mayr, Luzia M., et al.
Publicado: (2013)

Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies
por: Chikaev, A.N., et al.
Publicado: (2021)

Modeling Neutralization Kinetics of HIV by Broadly Neutralizing Monoclonal Antibodies in Genital Secretions Coating the Cervicovaginal Mucosa
por: McKinley, Scott A., et al.
Publicado: (2014)

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections
por: Wagh, Kshitij, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_67k3lemnjlbomqg96qtlsjgkle